Xilio Therapeutics Files 8-K on Shareholder Matters
Ticker: XLO · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1840233
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
Related Tickers: XLO
TL;DR
Xilio Therapeutics filed an 8-K for a shareholder vote on June 13th.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the company's corporate structure and reporting information, including its principal executive offices located at 828 Winter Street, Waltham, Massachusetts.
Why It Matters
This filing indicates that Xilio Therapeutics held a vote of its security holders, which is a standard corporate governance event. The details of the vote are not specified in this initial report.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure regarding a shareholder vote and does not contain information about significant financial events or strategic changes.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- June 17, 2024 (date) — Date of report
- 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (address) — Principal Executive Offices
FAQ
What was the specific purpose of the vote by Xilio Therapeutics' security holders?
The filing does not specify the exact proposals or matters voted upon by the security holders, only that a vote occurred on or before June 13, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 13, 2024.
What is Xilio Therapeutics' principal executive office address?
The principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the SEC file number for Xilio Therapeutics?
The SEC file number for Xilio Therapeutics is 001-40925.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-17 16:06:44
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
Filing Documents
- xlo-20240613x8k.htm (8-K) — 55KB
- 0001558370-24-009247.txt ( ) — 176KB
- xlo-20240613.xsd (EX-101.SCH) — 3KB
- xlo-20240613_lab.xml (EX-101.LAB) — 16KB
- xlo-20240613_pre.xml (EX-101.PRE) — 10KB
- xlo-20240613x8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 13, 2024, Xilio Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters. 1. The Company's stockholders elected Paul J. Clancy and Christina Rossi as Class III directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class III directors were as follows: Votes For Votes Withheld Broker Non-Votes Paul J. Clancy 18,450,957 1,087,467 6,783,293 Christina Rossi 18,451,038 1,087,386 6,783,293 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders' vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining 26,199,617 101,371 20,729
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Christopher Frankenfield Christopher Frankenfield Chief Operating Officer